Who Gets a Seat at the Table? The Diversity Problem in Cancer Clinical Trials

Every new cancer drug, every breakthrough therapy, every treatment protocol that saves lives tomorrow — it all starts in a clinical trial today. Which raises an uncomfortable question: if certain communities are consistently left out of those trials, are we building tomorrow's medicine for everyone, or just for some?

Clinical trial disparities occur when certain populations face lower participation, limited access, or reduced eligibility for cancer research. The consequences aren't abstract — they show up later as fewer treatment options and lower survival rates for the very groups who were underrepresented in the research.

Who Gets Left Out Most

Indigenous peoples. Black communities. Rural residents. Low-income patients. Immigrants and newcomers. Older adults. Patients managing multiple chronic conditions. Each group faces its own version of the same structural wall.

Why This Keeps Happening

Trials cluster in large urban cancer centers, creating a geographic barrier before anyone even applies. Add transportation costs, unpaid time off work, childcare needs, provider assumptions about who might be "interested," strict eligibility criteria that exclude common comorbidities, dense consent paperwork, historical mistrust rooted in real unethical practices, and outreach efforts that rarely reach beyond major medical centers.

The Cost of Underrepresentation

Reduced access to cutting-edge therapies. Lower survival rates for aggressive disease. Fewer treatment options when standard care isn't enough. Research data that doesn't reflect the full population it's meant to serve. Slower adoption of promising new treatments in the communities that need them most.

Where the Gaps Show Up Most Starkly

Breast cancer trials underrepresenting Black and Indigenous women. Prostate cancer trials with limited Black male participation, despite Black men facing significantly higher risk. Lung cancer trials that exclude rural patients simply due to travel distance. Colorectal cancer trials with low participation among low-income and rural populations.

What Could Actually Fix This

Decentralized trials that bring local labs and telehealth visits to patients, instead of requiring patients to come to a major center. Community-based recruitment. Culturally tailored education about what trials actually involve. Real financial support for travel and lodging. Simplified consent forms. Broader eligibility criteria. Genuine partnerships with Indigenous, Black, and rural health organizations — not just outreach to these communities, but collaboration with them.

How AskEddy Helps

AskEddy explains trial options in plain language, helps patients prepare sharp questions for their oncologist, clarifies confusing eligibility criteria, and supports shared decision-making — becoming a bridge toward advanced care that too often feels out of reach.

Reviewed by Dr. Derrick J. Beech, MD, FACS, Surgical Oncologist

Sources: National Cancer Institute — Disparities in Clinical Trial Participation; FDA — Diversity in Clinical Trials